Skip to content
AwardedMLTGoods€816,863

CT2377/2025 - Framework Contract for the supply of Ustekinumab 45mg Solution for Injection, Ustekinumab 90mg Solution for Injection , and Ustekinumab 130mg Concentrate for Solution for Infusion

Published
Published 15 December 2025
Deadline
Closed 5 February 2026

Overview

A framework contract for the supply of Ustekinumab pharmaceutical products in three formulations (45mg, 90mg solution for injection, and 130mg concentrate for infusion) has been awarded to Mint Health Limited for €239,689.54 on 20 May 2026. The contract was estimated at €816,863 and is now complete.

Key details

Country
MLT
Status
Awarded
Category
Goods
Estimated value
€816,863
Procedure
Open
Published
15 December 2025
Deadline
Closed
Classification (CPV)
Toxins

Award outcome

Awarded value
€239,690
Award date
20 May 2026
Winner
  • Mint Health Limited

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    3 June 2026

  2. Contract Notice

    13 January 2026

  3. Contract Notice

    7 January 2026

  4. Contract Notice

    15 December 2025

Contracting authority

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: CT2377/2025 - Framework Contract for the supply of Ustekinumab 45mg Solution for Injection, Ustekinumab 90mg Solution for Injection , and Ustekinumab 130mg Concentrate for Solution for Infusion — won by Mint Health Limited — Skim